Table 1.
Umbilical cord blood (UCB)-derived natural killer (NK) cells-based therapies were used currently in the clinical trials.
| Clinical trial identifier | Disease | Trial phase | The number of estimated Enrollment | Type of transplant | Conditioning | The date of NK infusion | Sponsor |
|---|---|---|---|---|---|---|---|
| NCT03019640 | B-Cell NHL | Phase 2 | 40 | auto-HSCT | Carmustine +etoposide +cytarabine+ melphalan+lenalidomide | Day −5 before transplantation | M.D. Anderson Cancer Center |
| NCT02280525 | Leukemia, Lymphoma | Phase 1 | 8 | non-HSCT | Flu+CY+lenalidomide± rituximab | Day 0 | M.D. Anderson Cancer Center |
| NCT00354172 | Leukemia, MDS | Phase 2 | 16 | UCB-SCT | CY+Flu+TBI | Day −5 before transplantation | Masonic Cancer Center, University of Minnesota |
| NCT02955550 | MM | Phase 1 | 15 | auto-HSCT | Melphalan | Days +7 to +14 after transplantation | Celularity Incorporated |
| NCT02781467 | AML | Phase 1 | 10 | non-HSCT | CY+Flu | Day 0 | Celularity Incorporated |
| NCT04347616 | AML | Phase 1, Phase 2a | 24 | non-HSCT | CY+Flu | Day 0 | Radboud University |
| NCT01619761 | ALL, AML, CLL. HL, MDS, NHL, SLL | Phase 1 | 13 | UCB-SCT | Flu, melphalan, lenalidomide ± rituximab | Day −2 | M.D. Anderson Cancer Center |
| NCT01729091 | MM | Phase 2 | 72 | auto-HSCT | Elotuzumab+lenalidomide+Melphalan | Day −5 before transplantation | M.D. Anderson Cancer Center |
| ChiCTR2000030622 | AML | Phase 1 | 20 | non-HSCT | NR | Two days after consolidation chemotherapy | PLA Air Force General Hospital, China |
| NCT03056339 | CD 19 positive B-lymphoid malignancies (ALL, NHL, CLL) | Phase 1, Phase 2 | 36 | non-HSCT | Flu+CY | Day 0 | M.D. Anderson Cancer Center |
| NCT01729091 | MM | Phase1, 2 | 72 | auto-HSCT | melphalan+lenalidomide | Day −5 before transplantation | M.D. Anderson Cancer Center |
| EudraCT number 2010-018988-41 | AML | Phase 1 | NR | non-HSCT | Flu+CY | Day 0 | Radboud Medical Centre, Nijmegen, Netherlands |
AML, Acute myeloid leukemia; NHL, Non-Hodgkin’s Lymphoma; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndromes; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; HL, Hodgkin’s Lymphoma; MM, Multiple Myeloma; auto-HSCT, autologous hematopoietic stem cell transplantation; UCB-HSCT, umbilical cord blood-hematopoietic stem cell transplantation; non-HSCT, no combined hematopoietic stem cell transplantation; CY, cyclophosphamide; Flu, fludarabine; TBI, total body irradiation; NR, no report.